Compare Eli Lilly And Co (LLY) vs Xylem, Inc. (XYL) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

Xylem (XYL) trades at $120.64, down 1.74% over 24 hours, with a bullish technical signal from moving averages and strong support near $118. The company reported consistent earnings beats, with Q1 2026 EPS of $1.12 exceeding the $1.08 estimate, and revenue growth from $5.5B in 2022 to $9.04B in 2025. Recent developments include a partnership with Gross-Wen Technologies and leadership appointments, reinforcing its position in water solutions.

Outlook remains positive with a consensus price target of $153, implying 27% upside, though risks include execution of growth initiatives and macroeconomic pressures on industrial demand. The stock offers a dividend yield supported by 16 consecutive years of increases, appealing for long-term investors seeking water infrastructure exposure.